Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib

Wenlong Li, Rolf W. Sparidans, Margarida L.F. Martins, Mujtaba El-Lari, Maria C. Lebre, Olaf van Tellingen, Jos H. Beijnen, Alfred H. Schinkel

Mol Cancer Ther (2021) 20 (6): 1173–1182.

https://doi.org/10.1158/1535-7163.MCT-20-0705

Published: 01 June 2021

View articletitled, ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib

Includes: Supplementary data

Journal Articles

OATP1A/1B Transporters Affect Irinotecan and SN-38 Pharmacokinetics and Carboxylesterase Expression in Knockout and Humanized Transgenic Mice

Dilek Iusuf, Marion Ludwig, Ahmed Elbatsh, Anita van Esch, Evita van de Steeg, Els Wagenaar, Martin van der Valk, Fan Lin, Olaf van Tellingen, Alfred H. Schinkel

Mol Cancer Ther (2014) 13 (2): 492–503.

https://doi.org/10.1158/1535-7163.MCT-13-0541

Published: 09 February 2014

View articletitled, OATP1A/1B Transporters Affect Irinotecan and SN-38 Pharmacokinetics and Carboxylesterase Expression in Knockout and Humanized Transgenic Mice

Includes: Supplementary data

Journal Articles

Abstract A148: Palomid 529, a dual mTor1/2 inhibitor, efficiently penetrates the blood‐brain barrier and may be an attractive agent for treatment of glioblastoma

Lin Fan, Levi Buil, Jos H. Beijnen, David Sherris, Olaf van Tellingen

Mol Cancer Ther (2009) 8 (12_Supplement): A148.

https://doi.org/10.1158/1535-7163.TARG-09-A148

Published: 10 December 2009

View articletitled, Abstract A148: Palomid 529, a dual mTor1/2 inhibitor, efficiently penetrates the blood‐brain barrier and may be an attractive agent for treatment of glioblastoma

Journal Articles

Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo

Maria L. H. Vlaming, Anita van Esch, Zeliha Pala, Els Wagenaar, Koen van de Wetering, Olaf van Tellingen, Alfred H. Schinkel

Mol Cancer Ther (2009) 8 (12): 3350–3359.

https://doi.org/10.1158/1535-7163.MCT-09-0668

Published: 09 December 2009

View articletitled, Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo

Includes: Supplementary data

Journal Articles

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1^−/−/Mdr1a/1b^−/− (triple-knockout) and wild-type mice

Serena Marchetti, Nienke A. de Vries, Tessa Buckle, Maria J. Bolijn, Maria A.J. van Eijndhoven, Jos H. Beijnen, Roberto Mazzanti, Olaf van Tellingen, Jan H.M. Schellens

Mol Cancer Ther (2008) 7 (8): 2280–2287.

https://doi.org/10.1158/1535-7163.MCT-07-2250

Published: 21 August 2008

View articletitled, Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice

Journal Articles

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2

Serena Marchetti, Roos L. Oostendorp, Dick Pluim, Monique van Eijndhoven, Olaf van Tellingen, Alfred H. Schinkel, Richard Versace, Jos H. Beijnen, Roberto Mazzanti, Jan H. Schellens

Mol Cancer Ther (2007) 6 (12): 3307–3313.

https://doi.org/10.1158/1535-7163.MCT-07-0461

Published: 18 December 2007

View articletitled, In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2

Journal Articles

Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C

John D. Allen, Arnold van Loevezijn, Jeany M. Lakhai, Martin van der Valk, Olaf van Tellingen, Glen Reid, Jan H. M. Schellens, Gerrit-Jan Koomen, Alfred H. Schinkel

Mol Cancer Ther (2002) 1 (6): 417–425.

Published: 01 April 2002

View articletitled, Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib

OATP1A/1B Transporters Affect Irinotecan and SN-38 Pharmacokinetics and Carboxylesterase Expression in Knockout and Humanized Transgenic Mice

Abstract A148: Palomid 529, a dual mTor1/2 inhibitor, efficiently penetrates the blood‐brain barrier and may be an attractive agent for treatment of glioblastoma

Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1^−/−/Mdr1a/1b^−/− (triple-knockout) and wild-type mice

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2

Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C

Email alerts

AACR Journals

Update search

ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib

OATP1A/1B Transporters Affect Irinotecan and SN-38 Pharmacokinetics and Carboxylesterase Expression in Knockout and Humanized Transgenic Mice

Abstract A148: Palomid 529, a dual mTor1/2 inhibitor, efficiently penetrates the blood‐brain barrier and may be an attractive agent for treatment of glioblastoma

Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2

Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1^−/−/Mdr1a/1b^−/− (triple-knockout) and wild-type mice